Related Experiment Video

Updated: Jun 28, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

Identification of molecular targets in urologic oncology

Christopher P Evans1

  • 1Department of Urology, Davis School of Medicine, University of California, 4860 Y St., Suite 3500, Sacramento, CA, 95817, USA. cpevans@ucdavis.edu

World Journal of Urology
|November 13, 2008
PubMed
Abstract

Insights

Identifying molecular targets and biomarkers is crucial for advancing cancer diagnosis and therapy. This research explores their role in urologic cancers, offering insights for personalized medicine.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology
  • Pathology

Background:

  • Molecular targets have gained prominence in cancer diagnosis and therapy over the past decade.
  • Identification relies on advancements in genetics, biochemistry, molecular tumor biology, and pathology.

Purpose of the Study:

  • To review molecular targets and biomarkers in bladder, prostate, and renal cancers.
  • To analyze target development and clinical translation in urologic oncology.

Main Methods:

  • Systematic literature search of MEDLINE/PubMed for molecular targets, targeted therapy, and biomarkers.
  • Analysis of existing literature combined with author's expertise and laboratory data.

Main Results:

  • Molecular targets often function as prognostic or predictive biomarkers.
  • Targets in urologic cancers originate from the host, tumor, treatment, or disease stage.
  • Understanding target progression is key for diagnostics, personalized medicine, and targeted therapeutics.

Conclusions:

  • Identifying molecular events, signals, and pathways in urologic cancers presents opportunities for diagnostic and therapeutic biomarker development.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...